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Introduction 
In the future, animal and human donor cell models may not be the first choice for 
understanding mechanisms of disease, cancer and their treatments. A main factor is the poor 
evidence of animal models for efficacy in humans,
[1]
 ethical issues with increasing 
restrictions in animal transport from overseas
[2]
 and cost of higher developed animals such as 
primates that would provide close in vivo resemblance of human tissues. Human donor 
tissues are of limited availability and certain genetic predisposition that remain undetected 
impact on the interpretability of the outcome. In vitro models, on the other hand allow 
systematic repetitive, in-depth and quantitative studies of physiological and 
pathophysiological processes without having to deal with complications that are associated 
with animal and donor tissues such as keeping cells in viable conditions for a long period of 
time. While most of in vitro models have been successfully created in the two-dimensional 
(2D) “monolayer” medium,  2D models for studying for example tumour cell growth in 
plastic dishes have been compared to “...training for a desert war in the arctic”.[3] A more 
complex and purer approach is to provide a three dimensional (3D) “microenvironment” to 
the cells studied, by resembling the cells’ interstitial fluid and extracellular matrix (ECM) as 
they experience these under in vivo conditions. The logic behind this 3D approach is that this 
model allows cells to crosstalk with their microenvironment which may initiate events at 
cellular and molecular levels including changes in cell differentiation, morphogenesis, 
motility, secretory function and gene expression.
[4, 5]
 Hence in a 3D structure, cells can 
recapitulate their original structure similar to in vivo conditions. It is believed that those 
“cues” from the microenvironment are necessary for the cells to differentiate and thus such 
3D conditions allow the study of in vivo cellular events. The culture of cells in 3D has been 
successfully applied over 20 years using basement membrane gels (e.g Matrigel, Engelbreth-
Holm Swarm (EHS) matrix) with hundreds of articles published (for review 
[6]
). However, 
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the use of 3D models for mimicking disease processes such as cancer, osteoarthritis, organ 
models, etc. is only making its entrance and has opened an entire new area as tissue engineers 
translate their concepts into this new research arena.
[3]
  
 
Three-dimensional cell models can be established from cell lines, dissociated tissues, 
progenitor cells and stem cells of one or more cell types that have been cultured in the dish 
and then seeded into scaffolds (cellular solids) and matrices (hydrogels) made out of 
biomaterials.
[7]
 Scaffolds/matrices need to provide mechanical stability, suitable geometry 
and provide appropriate biochemical/biophysical cues to allow cells to grow and differentiate. 
Advancements in the quality of these components are continuously evolving with the aim to 
develop materials that encourage key interactions within cells “...that unlock the body’s 
innate powers of organisation and self repair” (for review[8]). Not every organ model 
however, may be satisfactorily mimicked, with challenges such as choosing the right ECM, 
lack of microvascular supply and proper immunoresponse, cell specific polarity as well as 
various cell-cell and cell-matrix interactions that have to be considered.
[5]
 Creating a 
functional vasculature and understanding endothelial cell - ECM communication is one of 
challenges in tissue engineering (for review
[9]
). Integrins are thought to play key roles not 
only in providing the anchorage of endothelium to the ECM but are also important in cell 
activation and signal transduction mediated by soluble factors such as vascular endothelial 
growth factor (VEGF). Abnormal interactions can be found in certain microvascular diseases, 
and VEGF blockage, has been extensively studied as a therapeutic in the treatment of 
cancers,
[10]
 age-related macular degeneration (AMD)
[11]
 and diabetic retinopathy
[12]
 with the 
aim to block abnormal vascular cell growth.  
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In addition, the phenotypic behaviour of cells does not only depend on biological stimuli 
imposed by the ECM but also on mechanical stimuli. The ECM stiffness (compliance) which 
includes rigidly, elasticity and pliability directs cell-matrix interactions with cell integrin 
receptors and cytoskeleton sensing the changes and adapting accordingly.  For example there 
is evidence that dermal fibroblasts proliferate better in stiffer ECM and migrate faster in 
softer ECM
[13]
 and preosteoblastic cells exhibit different migration patterns dependent on 
ECM stiffness.
[14]
  Moreover, medium sized ECM pore diameters, and conditions with most 
matrix stiffness and adhesivity cause maximum migration of marrow-derived stem cell.
[15]
  
Hierarchical cell arrangements need to be also considered allowing controlled flows of 
interstitial, vascular and lymphatic fluids.
[7]
  
 
Three dimensional systems require rigorous testing before they can be considered as models 
mimicking certain cascades of the in vivo model yet major steps have been made, suggesting 
that they will become powerful tools for studying and simulating physiological processes. In 
the following we will briefly describe some of these models and propose a novel 3D model of 
the eye structures that are involved in the most common cause of blindness in the Western 
World, age-related macular degeneration (AMD). 
 
Current 3D models 
To study tissue for the purpose of understanding organ systems and disease mechanisms has 
been not only a longstanding interest for medical professionals and scientists. Leonardo da 
Vinci has described most of the human organs in his extensive anatomical studies where he 
dissected and drew organs with finest precision. Once after he had witnessed the peaceful 
death of a man, he was keen to dissect the heart “to see the cause of so sweet death”. He was 
the first to described coronary narrowing and coronary heart disease due to atherosclerosis. In 
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tissue engineering however, the “artist” is trying to understand principles not by dissecting 
tissue, but by building tissue replicates based on their behaviours using a various range of 
biomaterials that allow the resemblance of in vivo conditions.  
 
Two cell patterning technologies have been used for tissue fabrication, the top-down 
scaffold-based and the bottom up approach.
[16]
 The top-down scaffold based approach relies 
on cells being seeded on a scaffold to allow for maturation in a bioreactor whereas the 
bottom-up approach uses layer stacking, random packing or 3D printing to assemble  small 
cell laden so called “building blocks” that mimic native functional units, into larger tissue 
constructs promoting self-sorting and self-assembly of cells. The latter is divided into 
mesoscale and microscale technologies allowing either cell laden building blocks assembly in 
the order of 400mm thickness or assembly into smaller units in a microscale range, 
respectively with both technologies combined being considered as “the Holy Grail of 
engineering thick tissues that feature a functional histoarchitecture”.[16]   
 
Current 3D models serve four major purposes: Replacement/repair of organs by mimicking 
their tissue structure, the study of tumour growth/cancer, the study of (non cancerous) disease 
pathomechanisms and the study of treatment effects. While 3D models of organ replacement 
and repair have been studied for about a decade now, tumour growth and disease concepts 
models are just emerging in the last few years (for review
[4]
). We would like to refer to 
excellent reviews on these models e.g.
[4-6, 8, 17, 18]
 as well as give examples of our own 
research and a few of the 3D disease model concepts below. 
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1. Mimicking organotypic structures  
Although the field of 3D in vitro models is still in its early development, numerous scenarios 
exist to pursue sophisticated biological hypotheses by combining a versatile biomaterials and 
bioengineering toolbox with rich molecular characterization of specific cell types, one can 
begin in vitro experiments to investigate mechanisms of differentiation and development, to 
model multicellular disease states in a feasible and realistic context, and to define intricate 
cell growth and differentiation platforms for use in different disease models.  
 
Three-dimensional tissue cultures models for example of the liver,
[19-22]
 skin and mucosa,
[23, 
24]
 peripheral neurons,
[25]
 myocardium,
[26-28]
 bladder,
[29]
 trachea,
[30]
 vessels,
[31]
 bones,
[32]
 
cartilage,
[18, 33]
 and cornea (for review
[34]
) have been introduced. An impressive example of 
overcoming the challenge of mimicking a complex capillary system is the rat liver model, 
that integrates 3D microscale tissue with flow using a microarray bioreactor that allows 
formation of sinusoidal liver capillaries (e.g
[7, 20]
). The microarray bioreactor comprises a 
silicon or plastic chip that holds an array of channels akin to the liver sinusoidal capillary 
bed. Liver cells are seeded into the channels, cells adhere to the ECM coated channel walls 
and form tissue structures. A filter allows even flow of culture medium that is pumped 
through the channels based on oxygen metabolism of the tissue and local shear stress. Newer 
approaches have brought this channel system forward to a simpler “easy to use” application 
using a multiwell plate that allows for higher throughput.
[22]
 The multiwell plate hosts an 
array of 12-24  bioreactors were each consist of a reactor well that contains the ECM coated 
scaffold and a reservoir well. The latter contains the culture medium which is continually 
pumped through the scaffold with an integrated pneumatic micropump for each of the 
reactors. Experimental measures of primary rat hepatocytes seeded onto the channels 
indicated that oxygen consumption of cells on the scaffolds was similar to that in perfused rat 
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livers. Likewise long term survival of the sinusoidal endothelial liver cells was good with the 
expression of functional markers of up to 13 days of co-culture with hepatocytes. The authors 
suggest this 3D model to be useful for other highly metabolic and vascularised tissues such as 
kidney, brain or heart.  A recently introduced model with human hepatocytes (HepaRG) 
shows promise for toxicology testing. Leite et al.
[35, 36]
 cultured hepatocytes in stirred 
bioreactors (spinner vessels) after full differentiation in 2D monolayers for the purpose of 
long term stability of hepatocytes function. The resulting HepaRG spheroids developed 
biliary like and hepatocytes like cells that demonstrated typical liver function properties such 
as enzyme activity, albumin secretion and long term functionality of up to 7 weeks. 
Cytotoxicity testing demonstrated concentration dependent decrease of cell viability. This 
model may be a promising alternative for evaluating long term drug effects of xenobiotics. 
 
While the liver 3D model is relatively new, cardiac myocytes have been shown to grow 
extraordinarily well in 3D context in the late 90ties
[37]
 with research progressing now into 
growing new hearts from cadaveric pig matrices in the 21
st
 century.
[38]
 One of the challenges 
of building new heart tissues is the cardiomyocites high oxygen and metabolic demand and 
organ reconstruction has been limited to cardiac patches.
[39]
 Taylor and her research team at 
University of Minnesota have overcome the problem by removing cellular constituents from 
the cadaveric pig/rat tissue but retaining the ECM and acellular vascular networks to serve as 
a 3D scaffold for newly seeded (neonatal) cells to form new vasculature.
[38]
 This approach 
has been successfully applied in the rat but a human model does not exist yet and further 
research is needed to understand what drives proliferation and differentiation of human stem 
cells in a cardiac scaffold. The researchers are optimistic and foresee human heart surrogates 
that can be used for drug screening and toxicity testing in the near future.  
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Another area where the translation of a tissue engineering concept  has been very successful 
is in providing a 3D skin model not only for regenerating skin of patients yet also as 
convincing example for the transition from 2 to 3D which has largely been made in the 
cosmetic industry. For many companies in this business the use of in vitro human skin 
equivalents for compound testing is imperatively needed to replace animal testing (legally 
banned from 2013).  
 
A “basic recipe” for 3D skin and mucosa has been introduced using human cultures of 
epithelial (keratinocytes) and stromal (fibroblasts) and acellular de epidermised dermis 
(DED) from cells isolated from human skin removed at various surgical procedures 
[23]
. 
Fibroblast enter the dermis through basement membrane only when keratinocytes are present, 
therefore fibroblasts and epithelial cells are co-cultured and placed on the uppermost part 
(papillary) surface of the DED. MacNeil et al.
[23]
 describe elegantly how these isolated 3D 
tissue engineered skin cells as well as buccal mucosa can achieve normal gross-morphology 
in about 14 days with constructs surviving long term after being grafted back. Tissue 
engineered skin can be used for wound healing assays, for studying aspects of skin 
contractions, pigmentation and melanoma development. Another 3D skin equivalent system 
has been developed using human neonatal epidermal cells that are cultivated on matrices 
serving as derma equivalent such as cell free porous ECM coated membranes or seeded with 
matrix embedded dermal fibroblasts.
[40]
 These organotypic cultures mimic native epidermis 
closely and promise to be powerful tools in the investigation of skin morphogenesis. Recent 
advancements in skin tissue engineering use 3D freeform fabrication (FF) techniques that 
allow the implementation of a robotic platform that prints human fibroblasts and 
keratinocytes using hydrogel as scaffold.
[24]
 This computer generated skin graft may lead to 
the printing of multilayered skin cells on demand.  
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2. Cancer models and treatment:  
Models of the reproductive system have been generated for ovarian 
[41]
, breast cancer 
[42, 43]
 
and prostate cancer.
[44, 45]
 Models for skin,
[46, 47]
 liver
[48, 49]
 and bladder
[50]
 cancer, Hodgkin 
lymphoma
[51]
 and neuroendocrine tumors
[52]
 have been also introduced. All cancer models 
have the common goal to better understand the pathomechanisms of tumor growth, in 
particular to understand the tumor-microenvironment interaction. One of the hallmarks of 
cancer cells is that they undergo unlimited proliferation as they do not respond to cellular 
cross talk as it would occur in healthy tissues.
[53]
 
 
To observe higher-order biological processes of cancer in 3D environments, cells have been 
cultured in collagen gels or Matrigel; both matrices allow cellular remodeling, and isotropic 
arrangement of extracellular matrix and chemical factors. These naturally derived materials 
enable cancer researchers to investigate cancer cell adhesion, migration, proliferation and 
differentiation and homeostasis of the cancer stem cell niche in a context that captures 
essential matrix cues.  
 
Early breast cancer models showed that breast epithelial cells cultured on Matrigel, 
demonstrate typical tumor cell growth as well as restoration of differentiation only in the 3D 
context but not in 2D due to appropriate spatial and biochemical cues from the 
microenvironment.
[54, 55]
 A cancer treatment model based on battling hypoxia as frequently 
encountered in the inside of tumors due to poor tissue perfusion, has been explored in ovarian 
cancer.
[41]
 Hypoxia itself causes an unfavourable acidic microenvironment that may hinder 
cellular uptake of the therapeutic. Ovarian cancer cells were cultured on ECM rich Matrigel 
over several days and developed into differently sized nodules to mimic metastatic tumors in 
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the peritoneum. It was demonstrated that the larger the cancer nodules were, the greater the 
central hypoxic areas. A coating of ECM materials with fibronectin, collagen IV and laminin 
V was found on the outsides of cancer nodules suggestive of being a physical barrier to 
treatment agents. Treatment with a photosensitiser that penetrated deeply enough into the 
cancer cell model was successful in killing the core cells of larger nodules and may give rise 
for a potential treatment of therapy resistant cancer ovarian cancer.  
 
Drug resistance is also a common problem in prostate cancer treatment. Cancer cells mimic 
their environment and change their gene expression to that of the surrounding cells. Prostate 
cancer cells for example express bone specific genes and display osteomimetic properties 
[56]
. 
Wang et al.
[45]
 have reviewed existing 3D prostate cancer models of cells cultured in 
Matrigel, chorioallantoic, agarose gel and synthetic matrices. They studied cancer cell 
behaviour and stromal interactions using the RWV 3D model, which mimics reduced gravity 
and where cells form 3D conglomerates due to fluid rotation.
[57]
 Another group of researchers 
has developed miniaturized 3D models in vitro of several prostate cancer cell lines as 
spheroids (prostaspheres) and in particular to investigate tumor cell growth, migration and 
invasion and to study inhibitors that block invasive behaviour.
[44]
 Their model suggests that 
cell lines may undergo a transformation from epithelial to mesenchymal cells, becoming 
more aggressive in their invasive patterns. This transformation is thought to be temporarily 
suppressed by interaction with the ECM.  
 
 
3. Studying disease concepts (other than cancer) and treatments:  
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Disease mechanisms models are just emerging, these include three dimensional models for 
studying inflammatory bowel disease (IBD) such as Crohn’s disease or Colitis ulcerosa,[58] 
autosomal dominant polycystic kidney disease,
[59, 60]
 Metabolic syndrome,
[61]
 periodontitis 
[62]
 
and age –related macular degeneration.[63] For example for studying IBD, inflammation can 
be stimulated by adding proinflammatory stimuli such as interleukin-1β and interferon-γ to 
human enterocytes cultured and seeded on top of macrophages and dendrites embedded in a 
collagen layer on a Transwell filter insert. This inflammatory bowel syndrome model induces 
greater inflammatory cytokine responses than the single cell culture and allows the additional 
study of the complexity of the disease.  
 
Genetically modified mouse embryonic kidney cells with or without defects in the tubular 
segments can be added onto collagen-matrigel-infused silk scaffolds to study polycystic 
kidney disease.
[59]
 Researchers showed that the combination of ECM proteins such as found 
in collagen- matrigel played an important role in mediating cystogenesis and tubulogenesis of 
the normal and diseased kidney cells and that co-culturing with fibroblast induced more 
tubule-like structures in the normal cells. The group further demonstrated abnormal ECM 
interactions mediated via integrin- β1 with aberrant matrix (collagen type IV and laminin) 
deposition and upregulation of integrin- β1 promoting cell proliferation and cyst progression 
in their 3D in vitro disease model.
[60]
 Their findings may help in the development of better 
targeted therapeutics. 
 
Oortgiesen et al.
[64]
 developed a potential 3D constructs that can be transplanted into 
defective periodontal sites but also may allow the study of mechanical forces on periodontal 
ligament (PDL) cells that occur during mastication. Wistar rat PDL fibroblasts were seeded 
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and cultured on osteogenic medium, mixed with collagen solution to provide a 3D matrix and 
then exposed to mechanical loading or a chemical stimulus. Their model may also allow 
investigating PDL cell responses to other stimuli in the future. 
 
A novel cell assembly technique (CAT) or so called “bottom up approach” has been 
developed for the evaluation of adipocytes, endothelial cells and pancreatic β-cells that are 
major players in metabolic syndromes such as obesity and diabetes.
[61]
 CAT is based on rapid 
prototyping and allows cells and materials to form 3D structures. For building the 3D 
structure, a mixture of gelatine, alginate and fibrinogen and adipocytes sourced from rats is 
used and a computer controlled CAT is applied. Following the designed 3D structure, a 
nozzle controlled by a computer deposits the mixture on a glass chip at low temperatures (10 
degree) and after several runs, forms the 3D structures. After cross-linking and 
polymerisation the construct does not loose integrity and adipocytes cell differentiation and 
organisation is facilitated.  This model allowed cells to keep up their bioactivities and 
functions as experienced in the in vivo environment such as β-cells secreting insulin. Long-
term exposure to glucose caused adipocytes to become “obese”. The study also provided 
important observations regarding crosstalk of cells via hormone secretion and may have 
implications on treatment strategies of metabolic disease such as obesity and diabetes which 
have become epidemic. 
 
 
A 3D culture model for age-related macular degeneration (AMD) 
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Another disease threatening our population as we age, is age-related macular degeneration 
(AMD).
[65]
 AMD is the major cause of blindness in developed countries and causes central 
vision loss due to either central chorioretinal atrophy (“dry” AMD) (Figure 1A) or 
chorioretinal neovascularisation (“wet” AMD) (Figure 1B).[66]  There is no cure for AMD 
but it is considered as an “accelerated” ageing process.  
        
The primary insult causing AMD however, is not known but it involves the following three 
structures of the eye: a vascular layer, called choriocapillaris (Chr); an extracellular matrix, 
called Bruch’s membrane (BrM) and an epithelial layer, called retinal pigment epithelium 
(RPE). The RPE is separated from Chr by the ultrathin (3 μM), semi-permeable BrM. 
Structurally, BrM consists of 5 layers; a core of elastin fibres, an outer and inner fibrous layer 
and the basement membranes of the RPE and choroidal endothelial cells. While the 
pathomechanisms leading to AMD are not fully understood, deposits- so called drusen build 
up between RPE and the BrM and contribute to its early stage (for review 
[67]
). Retinal 
pigment epithelium cell irregularities (hyper- or hypopigmentation) and drusen are the first 
clinical signs of a cascade of events leading to the ultimate death of the overlying 
neurosensory retina. Drusen are composed of proteins that are related to other degenerative 
disease such as arteriosclerosis, amyloidosis as well as proteins related to the immune and 
inflammatory response.
[68]
 The latter and evidence from numerous studies on gene 
polymorphisms in the complement factor H gene region suggest chronic inflammation being 
a major contributor to disease evolution and accounting for about 50% of AMD cases.
[69-71]
 
There is no treatment available to prevent the onset or progression of the more prevalent dry 
form of AMD.
[72]
 While current drugs designed to inhibit the activity of vascular endothelial 
growth factor (anti-VEGF therapies), can stabilize and/or improve vision in patients with 
neovascular AMD,
[73]
 visual and anatomical benefits can be only preserved when given 
A B 
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frequently over years.
[74]
 Novel treatment paradigms are continuously being explored 
[75]
 
warranting models for vigorous testing. The multifactorial nature of AMD however, has 
made it difficult to find one animal model that fits well with the full spectrum of disease and 
resembles the complex structure of a human retina.
[76]
 
 
First steps towards the development of an in vitro retinal 3-D tri layer model resembling RPE, 
Bruch’s membrane and choroid have been made by Hamilton et al.[63] In this model the 
ARPE-19 cell line and human umbilical vein-derived endothelial cells (HUVECs) were co-
cultured on amniotic membrane. Both, ARPE-19 and HUVECs formed continuous 
monolayers on each sides of the amnion and demonstrated typical morphology and adherence 
immunostaining for tight junctional proteins suggesting a potential use for studying the 
interactions between the three layers, and in particular age-related macular degeneration. 
Hamilton’s work can be however, extended and modified by using novel and innovative 
biomaterials that resemble Bruch’s membrane (BrM) for the study of pathomechanism in 
AMD (Figure 2A). The tri-layer retinal model could be stressed with factors such as 
oxidative stress
[77]
 and hypoxia that cause typical changes in AMD like  drusen formation, 
RPE irregularities
[78]
 (Figure 2B) and chorioretinal neovascularisation (Figure 2C), 
respectively. A hypothetical model for creating an in vitro 3D model for studying 
pathomechanisms AMD is proposed in the next section. 
 
Amnion is a suitable material for mimicking Bruch’s membrane due to similar characteristics 
such as resembling an epithelium and a basement membrane with components of collagen, 
lamina and elastin. However, it is much thicker than BrM and hence may not be suitable for 
studying pathophysiological processes that occur in AMD. Recently silk fibroin, from the 
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Bombyx mori silk worm has been introduced as an alternative for replacing corneal tissue 
and Bruch’s membrane.[34] Shadforth et al.[79]  have successfully developed a porous ultrathin 
membrane from the silk protein fibroin which supports the growth of RPE cells when coated 
with ECM proteins found within the RPE basement membrane, with the best results when 
coating with vitronectin (VN). Elastic fibres are important components of ECMs and are 
predominantly found in the central layer in BrM. Elastic fibres are produced from elastin 
through lysine mediated cross-linking of its s precursor Tropoelastin. Tropoelastin can 
resemble in a self association process called coacervation,
[80]
 it can form protein dense 
spherules 
[81]
 and mature elastin fibres.
[82]
 An advancement of Hamilton’s model could be the 
incorporation of Tropoelastin into the silk fibroin to mimic the elastic properties of BrM.  
 
A proof of concept of the liability of a novel tri layer 3D model based on a biomaterial and 
bioengineering tool box could be established by studying the pathophysiological processes of 
ageing and by introducing stressors of AMD. Increased ECM turnover that is associated with 
ageing BrM and clinically evident as thickening of BrM, could be stimulated to mimic 
structural and molecular changes driven by matrix metallo proteinasis (for review 
[83]
). An 
initial stressor that gives rise to first pathological changes within the retinal layers and in 
particular the RPE could be the induction of oxidative stress. The “smoking mouse” model 
where mice were exposed to Hydroquinone (HQ) is an excellent model for inducing such 
changes.
[84]
 HQ abundant in cigarette tar and HQ could be used to induce first changes in 
morpholology, ECM gene expression and function. One of the major properties of RPE are 
phagocytosis of photopigment outer segments and basal growth factor secretion. Functional 
studies of the RPE can determine dysfunction by mimicking ingestion of protein bound 
microspheres and measuring growth factor secretion, respectively.
[85]
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Further stressors of early AMD could be induced in a similar way as recently shown by 
Johnson et al.
[86]
 where primary human RPE cells were grown on 2 dimensional laminin-
coated porous support. Drusen formation was induced by exposing RPE cells to complement-
competent human sera. Typical sub RPE drusen like deposits (e.g containing APOE, 
clusterin, vitronectin, serum amyloid P component, and C5b-9 complement) were identified. 
These are promising findings suggesting that Johnson’s approach could be reproduced in a 
3D structured tri-layer model (Figure 2B).    
 
While one of the challenges in tissue engineering is the integration of vasculature within the 
TEC and/or de novo vessel formation, the challenge in neovascular AMD is to block new 
vessel formation.  A 3D model could be used to study stressors that lead to late neovascular 
AMD but also for studying abnormal cross-talk between choroidal endothelial cells and 
Bruch’s membrane at cellular-matrix level. Established stressors of neovascular choroidal 
neovascularisation (CNV) at microscopic level are breaks in Bruch’s membrane. Ryan[87] 
introduced one of the first primate models (Macaca speciosa) of experimental CNV which 
included transcleral or transvitreal injections of enzymes and laser induced disruption of 
Bruch’s membrane to create chorioretinal neovascularisation (CNV). They established the 
“break in Bruch’s membrane” and the “higher susceptibility of the macula” as important 
factors in the pathomechanisms of CNV formation. Laser breaks in BrM can be therefore 
introduced into the model to further allow the study of the development of (CNV).
[88]
 Other 
driving factors for CNV such as growth factor imbalance
[89]
 and hypoxia (for review
[67]
 can 
be mimicked easily and measured with established assays (e.g. 
[85]
) (Figure 2C).   
We are aware that this modified tri layer model is a concept that needs development, proof 
and thorough testing which we have now started in our laboratories. There will be challenges 
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as to how we can satisfactorily mimic a normal BrM with incorporation of elastin,  the aging 
BrM, the choice of appropriate cell lines (e.g. ARPE-19, HUVECs and primary cells), the 
successful co-culturing of these cell lines and yet formation of AMD typical changes such as 
drusen. However, we considered our hypothetical model as early yet first steps towards 3D 
modelling of a condition, that has been an ongoing challenge for ophthalmologist, scientists 
and medical professionals for more than four decades. While this is only the beginning, it 
cannot be denied that AMD is entering a new field of exciting research, the area of 3D tissue 
engineering. 
 
Conclusions 
During the past decades, a conversion from 2D to 3D cell culture has been taking place, in 
suspense to ensure greater physiological relevance of in vitro studies. We predict that in the 
21 century the application of 3D cell culture systems will increase dramatically and will 
impact areas such as and drug development/screening, yet will open up an entire new field 
namely in vitro disease models for example for AMD. Hence the future applications of AMD 
models of which are able to mimic disease may include a better understanding of underlying 
pathomechanisms and novel drug testing. AMD is a multifactorial condition that involves 
environmental, behavioural and genetic risk factors making it challenging to predict its 
manifestation in vivo.
[90]
 In particular, single nucleotide polymorphisms are highly 
influencing factors. Current cellular models of disease concepts do not account for genetics 
and in AMD, the determination of genotypes of cell lines may become important. Ideally cell 
culture models may investigate cell lines with AMD risk genotypes and cell lines without risk 
genotypes. 
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 Figure 1A, B. A. Early age-related macular degeneration with drusen and hypo- and 
hyperpigmentary changes of the retinal pigment epithelium (RPE). B. Late AMD with 
chorioretinal neovascularisation with sub and preretinal haemorrhages.  
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Figure 2A-C. A. The tri-layer model composed of fibroin (BrM), primary RPE and primary 
choroidal cells may be stressed to form B. early AMD typical changes such as RPE hyper- 
and hypopigmentation and drusen or C. Chorioretinal neovascularisation.  
 
